Funding round
Abcuro Series C
Abcuro, which works in biopharmaceutical research and development in Newton, raised $200M in a Series C round announced on 12 Feb 2025, led by New Enterprise Associates. 2 firms took part. It is Abcuro's third venture round on record; the one before was a Series B in Aug 2023.
$200M
Amount raised
Not disclosed
Post-money valuation
2
Investors
1 lead
Valuation
What this round says about the price
Abcuro did not disclose a valuation in this round. It came 18 months after Abcuro's Series B. It is 43% of the $463M Abcuro has raised in the venture rounds on record. Abcuro raised again 18 months later: a Series D round of $66M in Aug 2026.
Abcuro's funding rounds
Abcuro has 4 venture rounds on record. This one is highlighted.
Investors
Who put money in
New Enterprise Associates led the round with 1 other firm.
Lead investor
- New Enterprise Associates backs 286 venture-backed companies new investor
Also in the round
- backs 39 venture-backed companies new investor
Use of proceeds
What the money is for
According to the announcement, the money goes to product development.
- Product development
Comparable rounds
How it compares
30 Series C rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $74M, and this round was 2.7 times the median. The closest in time, other companies' Series C rounds in Pharmaceutical Products:
| Company | Announced | Amount | Post-money | Led by |
|---|---|---|---|---|
| AdvanCell Pharmaceutical Products | 13 Feb 2025 | $178M | not disclosed | not named |
| Pharmaceutical Products | 14 Jan 2025 | $100M | $800M | Double Point Ventures and DCVC |
| Pharmaceutical Products | 24 Mar 2025 | $29M | not disclosed | not named |
| Pharmaceutical Products | 11 Dec 2024 | $120M | not disclosed | Bain Capital Life Sciences |
| Pharmaceutical Products | 16 Apr 2025 | $115M | not disclosed | CTI Life Sciences Fund and Advent Life Sciences |
| Pharmaceutical Products | 20 Dec 2024 | $42M | not disclosed | M&G Investments |
| Pharmaceutical Products | 20 Dec 2024 | $16M | not disclosed | Iberis Capital |
| Pharmaceutical Products | 30 May 2025 | $26M | not disclosed | National Reconstruction Fund Corporation |
Sources
Where this comes from
Reported by 3 sources.
Questions
Frequently asked
How much did Abcuro raise in its Series C round?
Abcuro raised $200M in its Series C round, announced in Feb 2025.
Who led Abcuro's Series C round?
New Enterprise Associates led it, with Foresite Capital.
What was Abcuro's valuation at the Series C round?
It was not disclosed.
How does it compare with other Series C rounds in Pharmaceutical Products?
30 Series C rounds in Pharmaceutical Products within a year either side disclosed an amount; the median was $74M, and this round was 2.7 times the median.
Did Abcuro raise again after this round?
Yes: a Series D round in Aug 2026 of $66M.